First-Line Keytruda Treatment May Support Longer Mesothelioma Survival

first-line Keytruda treatment

New data suggests first-line Keytruda treatment helps lung cancer patients more than chemotherapy – even if chemotherapy patients add Keytruda later. The news is likely to have implications for people with pleural mesothelioma, too. German researchers presented the data earlier this week at the World Lung Cancer Conference in Barcelona.  The presentation was based on three years of the KEYNOTE-024 trial. The trial focused on lung cancer. But Keytruda is also an up-and-coming drug for malignant pleural mesothelioma. Pleural mesothelioma is a lung-related cancer similar to non-small cell lung cancer.  Blocking PD-L1 with First-Line Keytruda Treatment Keytruda is the brand name for pembrolizumab. It is an immune checkpoint inhibitor that blocks a protein called PD-L1. To be eligible for first-line … Continue reading First-Line Keytruda Treatment May Support Longer Mesothelioma Survival »

Lung Cancer Blood Test: Can it Find Early Mesothelioma?

lung cancer blood test for mesothelioma

Mesothelioma patients and their doctors may have reason to be optimistic about a new lung cancer blood test. A random trial of more than 12,000 high-risk people in Scotland shows the EarlyCDT test combined with CT imaging can detect cancer early. Earlier diagnosis is likely to lead to longer survival of lung cancers like pleural mesothelioma. Researchers presented their findings on the new lung cancer blood test at a global conference this week in Spain. Largest Lung Cancer Trial As in the US, lung cancer is the biggest cancer killer in Scotland. Pleural mesothelioma is a form of lung cancer. Although it is rare, mesothelioma is more common in the UK than in other parts of the world. This is … Continue reading Lung Cancer Blood Test: Can it Find Early Mesothelioma? »

Mesothelioma Tumor Response to Nivolumab Detailed in New Case Study

mesothelioma tumor response to nivolumab

An Indian woman in still alive two years after a mesothelioma diagnosis thanks to a remarkable mesothelioma tumor response to nivolumab. Nivolumab is sold under the brand name Opdivo. It is a type of immunotherapy. Nivolumab is sometimes used for lung cancer that progresses after chemotherapy. A hospital in Mumbai tried nivolumab on a pleural mesothelioma patient after several types of chemotherapy did not work. Doctors say the mesothelioma tumor response to nivolumab was so great that the patient no longer needed supplemental oxygen.  Opdivo in Mesothelioma Treatment Opdivo is not FDA-approved for mesothelioma treatment. Only Alimta (pemetrexed) holds that designation. But pleural mesothelioma grows quickly and is hard to treat. Even the gold standard therapies often do not work … Continue reading Mesothelioma Tumor Response to Nivolumab Detailed in New Case Study »

MicroRNA Signature for Mesothelioma Could Lead to Earlier Diagnosis

microRNA signature for mesothelioma

Australian researchers believe they have identified what amounts to a microRNA signature for mesothelioma in pleural effusion.  Pleural effusion is the name for excess lung fluid. Up to 90 percent of pleural mesothelioma patients develop a pleural effusion. Researchers at the University of Western Australia say this fluid contains a wealth of information that could improve mesothelioma diagnosis. They have recently identified a trio of RNA molecules in fluid samples that could serve as a microRNA signature for mesothelioma. This “signature” could help doctors distinguish mesothelioma from other types of cancer. The Challenge of Mesothelioma Diagnosis Pleural mesothelioma is notoriously hard to diagnose. The early symptoms of mesothelioma are similar to the symptoms of many other lung conditions. They are … Continue reading MicroRNA Signature for Mesothelioma Could Lead to Earlier Diagnosis »

CRS/HIPEC Treatment Helps Double Survival Among Swedish Mesothelioma Patients

CRS/HIPEC Treatment

A new report suggests that CRS/HIPEC treatment has helped to double the odds of surviving peritoneal mesothelioma in Sweden.  Researchers collected data from the Swedish National Cancer Registry. A total of 102 peritoneal mesothelioma cases were included from two separate 5-year time periods. The report shows that, since CRS/HIPEC treatment was introduced in Sweden, overall survival of peritoneal mesothelioma increased from 7 to 15 months. At 5 years, twice as many peritoneal mesothelioma patients were still alive. The researchers conclude that this is likely due, at least in part, to CRS/HIPEC treatment.  Surviving Peritoneal Mesothelioma Peritoneal mesothelioma is an aggressive cancer that starts on the membrane lining the abdomen. It is almost always caused by accidental swallowing of microscopic asbestos … Continue reading CRS/HIPEC Treatment Helps Double Survival Among Swedish Mesothelioma Patients »

New Hope for Relapsed Pleural Mesothelioma?

relapsed pleural mesothelioma

There is new evidence that adding a drug called vorinostat to immunotherapy might help relapsed pleural mesothelioma patients.  The new study comes from the Moffitt Cancer Center in Tampa. It focused on patients with non-small cell lung cancer. Non-small cell lung cancer is similar to pleural mesothelioma in many ways.  The study found that patients who received vorinostat along with an immune checkpoint inhibitor had better results. The findings could be good news for relapsed pleural mesothelioma patients, too. Different Immunotherapy Drugs Vorinostat is sold under the brand name Zolinza. It is a histone deacetylase (HDAC) inhibitor. HDAC inhibitors alter the way proteins are expressed inside cells. They also stimulate the immune system.  Immune checkpoint inhibitors (ICIs) like Keytruda also … Continue reading New Hope for Relapsed Pleural Mesothelioma? »

Effect of Chemotherapy on Immunotherapy for Mesothelioma

effect of chemotherapy on immunotherapy

Belgian scientists say they are still not sure about the effect of chemotherapy on immunotherapy for mesothelioma. They reached that conclusion after testing several different chemotherapy drugs on mesothelioma cells in the lab. The combination of chemotherapy and immunotherapy is “chemoimmunotherapy”. It aims to harness the unique powers of each treatment approach. A meta-analysis last May called chemoimmunotherapy the “next frontier” in mesothelioma treatment.  But the new Belgian study on the effect of chemotherapy on immunotherapy highlights how much doctors still do not know about the combo. Immune Checkpoints Are the Key When it is working properly, the immune system is supposed to find and kill cancer cells before they become mesothelioma tumors. But mesothelioma cells can hide from the … Continue reading Effect of Chemotherapy on Immunotherapy for Mesothelioma »

IMRT for Mesothelioma: Barriers to Completing Treatment

IMRT for mesothelioma

MD Anderson researchers say too many patients who might benefit from IMRT for mesothelioma never complete the treatment. The problem could be impacting their survival. Intensity Modulated Radiotherapy (IMRT) is a type of targeted radiation. It is designed to direct as much radiation as possible into the mesothelioma tumor without harming the surrounding tissue.  Patients who have a combination of surgery, chemotherapy, and IMRT for mesothelioma have the best odds of survival. But at MD Anderson Cancer Center, only two thirds of eligible patients completed IMRT after mesothelioma surgery. The new study aimed to find out why. Trimodal Therapy and Mesothelioma Survival Malignant mesothelioma rarely responds to a single cancer therapy. Trimodal therapy combines several different treatments to maximize success.  … Continue reading IMRT for Mesothelioma: Barriers to Completing Treatment »

Pleural Mesothelioma Rates Remain Stagnant As Survival Improves

pleural mesothelioma rates

A new report shows pleural mesothelioma rates in the US have failed to decline as they were predicted to do, but survival is improving slightly.  The US government began to implement tighter restrictions on asbestos in the 1970s. Researchers at the Cleveland Clinic say original projections had the incidence of pleural mesothelioma peaking in the early 2000s as a result. Pleural mesothelioma rates were supposed to decline after that. But numbers from the National Cancer Database (NCDB) tell a different story. They suggest that, while mesothelioma survival is improving, incidence of asbestos cancer are not. Asbestos and Malignant Mesothelioma Malignant mesothelioma is the most serious of a range of illnesses caused by asbestos. Pleural mesothelioma is the most common type … Continue reading Pleural Mesothelioma Rates Remain Stagnant As Survival Improves »

Curcumin Supplement Delays Mesothelioma Tumor Growth in Mice

curcumin supplement

Italian researchers say a curcumin supplement containing a compound found in black pepper slowed the growth of mesothelioma tumors in mice. The commercially available supplement is called Curcumin-C3complex/Bioperine. This is the first time this formulation has been studied for malignant mesothelioma.  Lab-grown human mesothelioma cells stopped growing when scientists treated them with the curcumin supplement. The treatment did the same in live mice.  The researchers suggest that the curcumin supplement may work synergistically with standard treatments.  What is in Curcumin-C3complex/Bioperine? Curcumin is the most bioactive compound in turmeric. Turmeric is the spice that gives curry its bright yellow color.  Several scientific studies suggest that curcumin and other curcuminoid compounds in turmeric have powerful health benefits. These compounds are anti-inflammatory and … Continue reading Curcumin Supplement Delays Mesothelioma Tumor Growth in Mice »

Get your free copy of
“Surviving Mesothelioma” Today!